212 related articles for article (PubMed ID: 25017487)
1. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
2. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.
Uchida K; Hoshinaga K; Watarai Y; Goto N; Kusaka M; Sasaki H; Hirano M;
Transplant Proc; 2014 Jun; 46(5):1314-8. PubMed ID: 24935294
[TBL] [Abstract][Full Text] [Related]
4. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
5. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.
Kovarik JM; Tedesco H; Pascual J; Civati G; Bizot MN; Geissler J; Schmidli H
Ther Drug Monit; 2004 Oct; 26(5):499-505. PubMed ID: 15385832
[TBL] [Abstract][Full Text] [Related]
6. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
8. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
Kovarik JM; Eisen H; Dorent R; Mancini D; Vigano M; Rouilly M; Hsu CH; Rordorf C
J Heart Lung Transplant; 2003 Oct; 22(10):1117-25. PubMed ID: 14550821
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial.
Wlodarczyk Z; Ostrowski M; Mourad M; Krämer BK; Abramowicz D; Oppenheimer F; Miller D; Dickinson J; Undre N
Ther Drug Monit; 2012 Apr; 34(2):143-7. PubMed ID: 22406656
[TBL] [Abstract][Full Text] [Related]
12. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
13. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
[TBL] [Abstract][Full Text] [Related]
14. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Langer RM; Hené R; Vitko S; Christiaans M; Tedesco-Silva H; Ciechanowski K; Cassuto E; Rostaing L; Vilatoba M; Machein U; Ulbricht B; Junge G; Dong G; Pascual J
Transpl Int; 2012 May; 25(5):592-602. PubMed ID: 22471345
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
17. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.
Pape L; Lehner F; Blume C; Ahlenstiel T
Transplantation; 2011 Sep; 92(6):658-62. PubMed ID: 21804444
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
[TBL] [Abstract][Full Text] [Related]
19. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of mycophenolic acid and kidney function during combined immunosuppressive therapy.
Oláh AV; Asztalos L; Ivády G; Varga E; Kovács AM; Kappelmayer J; Varga J
Clin Chem Lab Med; 2011 Nov; 49(11):1849-53. PubMed ID: 21848499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
